Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYCAMORE: REC-994 in Symptomatic Cerebral Cavernous Malformation
NCT05085561Phase 2Completed
- Sponsor
- Recursion Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tempol in cerebral cavernous malformation (CCM), sponsored by Recursion Pharmaceuticals. Started Mar 2022; status: completed.
02
Drugs
tempol
03
Conditions
cerebral cavernous malformation (CCM)
Beyond the preview
Go deeper on NCT05085561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085561.